FDA approves novel treatment to target abnormality in sickle cell disease - FDA Press Releases

FDA granted accelerated approval to Oxbryta (voxelotor) for the treatment of sickle cell disease in adults and pediatric patients 12 years of age and older

from FDA Press Releases RSS Feed https://ift.tt/2sh4rym
via IFTTT